---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-115933"
form_type: "8-K"
ticker: "PTGX"
cik: "0001377121"
company_name: "Protagonist Therapeutics, Inc"
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T03:12:20.977749+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Protagonist Q3 net loss $31.2M, cash $267.4M; rusfertide Phase 3 enrollment delayed to H2 2023

## Summary
- Net loss $31.2M ($0.64 per share) vs $33.8M ($0.70) in Q3 2021; no license revenue vs $10.3M.
- Cash and securities $267.4M as of Sep 30; expected to fund operations through end of 2024.
- Phase 3 VERIFY enrollment completion expected H2 2023 due to site staff shortages.
- Appointed Arturo Molina, M.D., M.S. as CMO, prioritizing rusfertide program.
- De-prioritized PN-943; no further internal resources; seeking out-licensing.

## SEC filing metadata
- accession: 0001104659-22-115933
- form_type: 8-K
- ticker: PTGX
- cik: 0001377121
- company_name: Protagonist Therapeutics, Inc
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1377121/000110465922115933/0001104659-22-115933-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1377121/000110465922115933/tm2229956d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-115933
- JSON: https://secwatch.observer/filing/0001104659-22-115933.json
- Plain text: https://secwatch.observer/filing/0001104659-22-115933.txt

## Key facts
- Earnings Releases
  Protagonist Therapeutics, Inc reported financial results for the third quarter ended September 30, 2022.
  - Period: the third quarter ended September 30, 2022
  - Result: reported results
  source text: Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist” or “the Company”) today reported financial results for the third quarter ended September 30, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1377121/000110465922115933/0001104659-22-115933-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.